AJP - Endo Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (September 14, 2004). doi:10.1152/ajpendo.00268.2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/1/E92    most recent
00268.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gagliardi, A. D.
Right arrow Articles by DiMattia, G. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gagliardi, A. D.
Right arrow Articles by DiMattia, G. E.
Submitted on June 22, 2004
Accepted on September 9, 2004

Human stanniocalcin-2 exhibits potent growth suppressive properties in transgenic mice independent of growth hormone and IGFs

Anthony D. Gagliardi1, Evan Y. W. Kuo1, Sanda Raulic2, Graham F. Wagner3, and Gabriel E. DiMattia4*

1 Department of Biochemistry, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada; London Regional Cancer Centre, London, Ontario, Canada
2 London Regional Cancer Centre, London, Ontario, Canada
3 Department of Physiology and Pharmacology, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
4 Department of Oncology, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada; Department of Biochemistry, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada; London Regional Cancer Centre, London, Ontario, Canada

* To whom correspondence should be addressed. E-mail: dimattia{at}uwo.ca.

STC-2 was discovered based on its primary amino acid sequence identity to the hormone, stanniocalcin (STC-1). The function of STC-2 has not been examined and we have generated two lines of transgenic mice overexpressing human STC-2 (hSTC-2) to gain insight into its potential functions through the identification of overt phenotypes. Our analysis of mouse Stc2 gene expression indicates that unlike Stc1, it is not highly expressed during development, but exhibits overlapping expression with Stc1 in adult mice, with heart and skeletal muscle exhibiting the highest steady-state levels of Stc2 mRNA. Constitutive overexpression of hSTC-2 resulted in pre and post-natal growth restriction beginning as early as E12.5 and progressing such that mature hSTC-2 transgenic mice are ~45% smaller than wild-type littermates. hSTC-2 overexpression is also sometimes lethal as we observed 26-34% neonatal morbidity without obvious dysmorphology. hSTC-2 induced growth retardation is associated with developmental delay most notably in cranial suture formation. Organ allometry studies show that hSTC-2- induced dwarfism is associated with testicular organomegaly and a significant reduction in skeletal muscle mass that likely contributes to the dwarf phenotype. The hSTC-2 transgenic mice are also hyperphagic, but this does not result in obesity. Serum Ca2+ and PO4 were unchanged in hSTC-2 transgenic mice even though STC-1 can regulate intra and extracellular calcium in mammals. Interestingly, the severe growth retardation induced by hSTC-2 is not associated with a decrease in growth hormone expression or that of the IGFs. Consequently, similar to STC-1, STC-2 can act as a potent growth inhibitor and reduce intramembranous and endochondral bone development and skeletal muscle growth implying that these tissues are specific physiological targets of stanniocalcins.




This article has been cited by other articles:


Home page
Physiol. GenomicsHome page
Y. S. Lee, K. E. Latham, and C. A. VandeVoort
Effects of in vitro maturation on gene expression in rhesus monkey oocytes
Physiol Genomics, October 8, 2008; 35(2): 145 - 158.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
S. Raulic, Y. Ramos-Valdes, and G. E DiMattia
Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro
J. Endocrinol., June 1, 2008; 197(3): 517 - 529.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
T Ichikawa, K Horie-Inoue, K Ikeda, B Blumberg, and S Inoue
Vitamin K2 induces phosphorylation of protein kinase A and expression of novel target genes in osteoblastic cells
J. Mol. Endocrinol., October 1, 2007; 39(4): 239 - 247.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Becker, B. Erdlenbruch, I. Noskova, A. Schramm, M. Aumailley, D. F. Schorderet, and L. Schweigerer
Keratoepithelin suppresses the progression of experimental human neuroblastomas.
Cancer Res., May 15, 2006; 66(10): 5314 - 5321.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. C.-M. Chang, J. Cha, F. Koentgen, and R. R. Reddel
The Murine Stanniocalcin 1 Gene Is Not Essential for Growth and Development
Mol. Cell. Biol., December 1, 2005; 25(23): 10604 - 10610.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.